My vision is to design patient and physician interventions that improve health outcomes in patients with rheumatic diseases such as gout, rheumatoid arthritis, and systemic sclerosis. My longstanding interest in gout research has led me to develop a focused expertise in this field. I have collaborated on several qualitative projects with various groups such as G-CAN, VA Crystal Registry, and OMERACT, an international collaborative effort on standardization of outcome measures in rheumatology. The American College of Rheumatology Foundation has funded me to assess quality of life in gout in veterans and led to the identification of gaps in treatment and knowledge. This work laid the foundation for development of a patient-centric website, MyGoutCare. I served as a Co-Investigator on the UO1 NIH/NIAMS PROMIS effort to develop and validate the GI-Symptoms Scale. I have been involved with development of gout guidelines and quality measures at national (ACR) and international levels (EULAR), and the latest guidelines on management of gout were published in May 2020. My clinical trial experience as principal investigator spans both acute and chronic gout with agents such as sodium bicarbonate, anakinra, febuxostat, lesinurad, pegloticase, and pegadricase; along with RA and Scleroderma studies. I recently completed a R21 grant funded by the NIAMS to study the effect of mycophenolate mofetil in mitigating the immunogenicity of pegloticase.